Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-14-0736
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Dacomitinib (PF-00299804), an Irreversible Pan-Her Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

Molecular Cancer Therapeutics
Cancer ResearchOncology
2012English

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Clinical Cancer Research
Cancer ResearchOncology
2015English

Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models With EGFR Activating Mutations, T790M Mutation and AXL Overexpression

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Is There a Role for Dacomitinib, a Second-Generation Irreversible Inhibitor of the Epidermal-Growth Factor Receptor Tyrosine Kinase, in Advanced Non-Small Cell Lung Cancer?

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2020English

Preclinical Activity of Selinexor, an Inhibitor of XPO1, in Sarcoma

Oncotarget
Oncology
2016English

YH25448, an Irreversible EGFR-TKI With Potent Intracranial Activity in EGFR Mutant Non-Small-Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2019English

MA26.11 Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

EGFR Signaling in the HGG-02 Glioblastoma Cell Line With an Unusual Loss of EGFR Gene Copy

Oncology Reports
MedicineCancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy